US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Skycorp Solar Group Limited

0.6513

-0.0237-3.51%

Post-market: 0.6468-0.0045-0.69%18:26 EDT

Volume:117.00K

Turnover:82.67K

Market Cap:17.59M

PE:596.43

High:0.7900

Open:0.6850

Low:0.6512

Close:0.6750

52wk High:4.45

52wk Low:0.6396

Shares:27.00M

Float Shares:10.35M

Volume Ratio:0.82

T/O Rate:1.13%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.0011

EPS(LYR):0.0188

ROE:4.46%

ROA:1.82%

PB:0.77

PE(LYR):34.57

Loading ...

Overview Company News Filings

European Advisory Panel Recommends Two AstraZeneca Drugs For Approval

Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion

Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

FiscalNote Holdings Issues Convertible Debentures to YA II PN

FDA Expands Approval For AstraZeneca's Drug For Pediatric Patients With Rare Type Of Cancer

Benzinga_recent_news

Skycorp Solar Group 1H Revenues $24,176,271, Up 7.53% YoY; Net Income $391,967, Down 39.09% YoY

Press Release: Skycorp Solar Group Limited Reports First Half 2025 Financial Results

Skycorp Solar Group Reports 7.53% Revenue Increase, 39.09% Net Income Decrease for First Half of 2025

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

Press Release: InnoCare Releases 2025 Interim Results and Business Highlights

Skycorp Solar Group Secures 8,705KW Solar Asset in $4.25 Million Deal

Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd

Skycorp Solar Group Ltd. Embraces Cryptocurrency Payments to Enhance Global Client Experience

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

Skycorp Solar Group Ltd. Announces Resignation of COO Gaokui Zhang Due to Health Reasons

BRIEF-Skycorp Solar Group Announces Board Authorization For Solar Photovoltaic Power Plant Acquisitions And Development

Intellia Says Enrollment in Late-Stage Study of NTLA-2002 on Track, of Nex-Z for ATTRv-PN Progressing Well

MT Newswires Live

Skycorp Solar Group Limited Appoints Feng Shibo To Board Of Directors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PN\",,,,,undefined,":{"symbol":"PN","market":"US","secType":"STK","nameCN":"Skycorp Solar Group Limited","latestPrice":0.6513,"timestamp":1758916800000,"preClose":0.675,"halted":0,"volume":116997,"hourTrading":{"tag":"盘后","latestPrice":0.6468,"preClose":0.6513,"latestTime":"18:26 EDT","volume":1985,"amount":1284.4225,"timestamp":1758925569070},"delay":0,"floatShares":10349999,"shares":27000000,"eps":0.001092,"marketStatus":"Market Closed","change":-0.0237,"latestTime":"09-26 16:00:00 EDT","open":0.685,"high":0.79,"low":0.6512,"amount":82668.9921279,"amplitude":0.20563,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.001092,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1759132800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1741064400000,"exchange":"NASDAQ","adjPreClose":0.675,"preHourTrading":{"tag":"盘前","latestPrice":0.675,"preClose":0.676,"latestTime":"08:00 EDT","volume":151,"amount":101.93000565,"timestamp":1758888014254},"postHourTrading":{"tag":"盘后","latestPrice":0.6468,"preClose":0.6513,"latestTime":"18:26 EDT","volume":1985,"amount":1284.4225,"timestamp":1758925569070},"volumeRatio":0.816378890204083},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PN\",,,,,undefined,":{"symbol":"PN","floatShares":10349999,"roa":"1.82%","roe":"4.46%","lyrEps":0.018839,"volumeRatio":0.816378890204083,"shares":27000000,"dividePrice":0,"high":0.79,"amplitude":0.20563,"preClose":0.675,"low":0.6512,"week52Low":0.6396,"pbRate":"0.77","psRate":"0.34","week52High":4.45,"institutionHeld":0,"latestPrice":0.6513,"eps":0.001092,"divideRate":0,"volume":116997,"delay":0,"ttmEps":0.001092,"open":0.685,"prevYearClose":4,"prevWeekClose":0.7901,"prevMonthClose":0.9267,"prevQuarterClose":2.767,"fiveDayClose":0.7901,"twentyDayClose":1.01,"sixtyDayClose":2.372},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-09-08","symbol":"PN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1757304000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PN\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PN","date":"2025-09-26","current":596.428571,"percent":0.916084,"low":53.124396,"twenty":139.188555,"median":161.061452,"eighty":216.579226,"high":992.177551,"avg":226.630635,"sd":213.775104,"marketCap":18225000},"quantilePoints":[{"date":"2025-03-07","current":218.413672,"twenty":221.509299,"median":227.299267,"eighty":241.802853,"marketCap":102870000},{"date":"2025-03-14","current":216.120615,"twenty":215.432698,"median":218.413672,"eighty":226.554024,"marketCap":101790000},{"date":"2025-03-21","current":214.974086,"twenty":214.74478,"median":217.840407,"eighty":223.401071,"marketCap":101250000},{"date":"2025-03-28","current":174.84559,"twenty":214.171516,"median":218.413672,"eighty":223.802356,"marketCap":82350000},{"date":"2025-04-04","current":196.629631,"twenty":205.707843,"median":216.693879,"eighty":223.802356,"marketCap":92610000},{"date":"2025-04-11","current":174.84559,"twenty":185.164346,"median":214.974086,"eighty":223.401071,"marketCap":82350000},{"date":"2025-04-17","current":144.462586,"twenty":175.992118,"median":213.827558,"eighty":222.942459,"marketCap":68040000},{"date":"2025-04-25","current":146.182379,"twenty":169.571559,"median":205.245792,"eighty":221.738604,"marketCap":68850000},{"date":"2025-05-02","current":139.876472,"twenty":146.182379,"median":196.629631,"eighty":219.789506,"marketCap":65880000},{"date":"2025-05-09","current":142.169529,"twenty":144.462586,"median":179.718336,"eighty":218.413672,"marketCap":66960000},{"date":"2025-05-16","current":143.241533,"twenty":143.318351,"median":174.84559,"eighty":217.95506,"marketCap":67464900},{"date":"2025-05-23","current":161.087249,"twenty":143.318351,"median":174.05162,"eighty":216.808532,"marketCap":75870000},{"date":"2025-05-30","current":166.246627,"twenty":143.435296,"median":166.533259,"eighty":216.020867,"marketCap":78300000},{"date":"2025-06-06","current":170.832741,"twenty":144.003975,"median":164.526834,"eighty":215.492317,"marketCap":80460000},{"date":"2025-06-13","current":161.087249,"twenty":144.462586,"median":163.380306,"eighty":214.859433,"marketCap":75870000},{"date":"2025-06-20","current":158.794192,"twenty":144.462586,"median":162.520409,"eighty":214.400822,"marketCap":74790000},{"date":"2025-06-27","current":148.475436,"twenty":144.462586,"median":162.233777,"eighty":213.827558,"marketCap":69930000},{"date":"2025-07-03","current":134.717094,"twenty":144.462586,"median":161.087249,"eighty":212.451724,"marketCap":63450000},{"date":"2025-07-11","current":144.462586,"twenty":143.775816,"median":159.914923,"eighty":208.466391,"marketCap":68040000},{"date":"2025-07-18","current":135.863623,"twenty":143.316058,"median":158.220928,"eighty":203.859639,"marketCap":63990000},{"date":"2025-07-25","current":171.979269,"twenty":143.316058,"median":158.708202,"eighty":199.725258,"marketCap":81000000},{"date":"2025-08-01","current":205.515227,"twenty":143.316058,"median":161.087249,"eighty":208.466391,"marketCap":96795000},{"date":"2025-08-08","current":142.169529,"twenty":143.316058,"median":161.087249,"eighty":205.923391,"marketCap":66960000},{"date":"2025-08-15","current":87.136163,"twenty":142.99503,"median":161.035655,"eighty":203.451475,"marketCap":41040000},{"date":"2025-08-22","current":59.906112,"twenty":140.908348,"median":158.42157,"eighty":199.725258,"marketCap":28215000},{"date":"2025-08-29","current":57.899687,"twenty":139.245882,"median":156.501135,"eighty":198.005465,"marketCap":27270000},{"date":"2025-09-05","current":59.046216,"twenty":137.927373,"median":155.927871,"eighty":197.088242,"marketCap":27810000},{"date":"2025-09-12","current":982.354011,"twenty":138.156679,"median":156.787767,"eighty":206.331555,"marketCap":27000000},{"date":"2025-09-19","current":835.885028,"twenty":138.672617,"median":158.622213,"eighty":214.056864,"marketCap":22974300},{"date":"2025-09-26","current":663.088958,"twenty":139.188555,"median":161.061452,"eighty":216.579226,"marketCap":18225000}],"updateTime":1759088493747},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2569732665","title":"European Advisory Panel Recommends Two AstraZeneca Drugs For Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2569732665","media":"Benzinga","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569732665?lang=en_us&edition=fundamental","pubTime":"2025-09-23 02:20","pubTimestamp":1758565200,"startTime":"0","endTime":"0","summary":"AstraZeneca and Amgen secure CHMP support for Tezspire in nasal polyps and Koselugo in neurofibromatosis after strong Phase 3 trial results.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/09/22/Konskie--Poland---January-03--2024-Astra.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/09/22/Konskie--Poland---January-03--2024-Astra.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/markets/large-cap/25/09/47801834/european-advisory-panel-recommends-two-astrazeneca-drugs-for-approval","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/large-cap/25/09/47801834/european-advisory-panel-recommends-two-astrazeneca-drugs-for-approval","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["PN","EMA","BK4096","BK4156","CHMP","BK4081","BK4087","ORR"],"gpt_icon":0},{"id":"2569082062","title":"Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion","url":"https://stock-news.laohu8.com/highlight/detail?id=2569082062","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569082062?lang=en_us&edition=fundamental","pubTime":"2025-09-22 12:29","pubTimestamp":1758515340,"startTime":"0","endTime":"0","summary":"Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo If approved, Dupixent would be the first targete","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/22/3153615/0/en/Dupixent-dupilumab-to-Treat-Chronic-Spontaneous-Urticaria-CSU-Advances-in-EU-with-Positive-CHMP-Opinion.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1829250122.USD","LU2237438978.USD","LU0823434740.USD","BK4007","LU0109394709.USD","BK4201","IE00BFXG1179.USD","LU0162691827.USD","BK4156","LU0072461881.USD","LU0289739699.SGD","LU2468319806.SGD","LU2362541513.USD","LU1917777945.USD","BK4588","LU2362540622.SGD","LU2089984988.USD","LU0882574055.USD","BP","LU2362541273.HKD","LU0053666078.USD","LU1974910355.USD","LU0823434583.USD","LU2023250504.SGD","LU0889565916.HKD","LU0058720904.USD","BK4096","SNY","PN","LU0320765646.SGD","BK4087","LU0114720955.EUR","LU2106854487.HKD","REGN","LU1162221912.USD","CHMP","BK4139","BK4585","LU0320765992.SGD","LU0823416689.USD"],"gpt_icon":0},{"id":"2568983594","title":"Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses","url":"https://stock-news.laohu8.com/highlight/detail?id=2568983594","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568983594?lang=en_us&edition=fundamental","pubTime":"2025-09-17 19:00","pubTimestamp":1758106800,"startTime":"0","endTime":"0","summary":"Featured presentations showcase the positive Phase 1 healthy volunteer trial results supporting KT-621’s oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/17/3151487/0/en/Kymera-Therapeutics-Announces-Late-Breaking-Oral-Presentations-on-KT-621-a-First-In-Class-Oral-STAT6-Degrader-at-the-European-Academy-of-Dermatology-Venereology-and-European-Respir.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4096","KT","LU0541502299.USD","BK4132","PN","AD","BK4139","LU0541501648.USD","BK4115","KYMR"],"gpt_icon":0},{"id":"2568446197","title":"Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2568446197","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568446197?lang=en_us&edition=fundamental","pubTime":"2025-09-17 17:11","pubTimestamp":1758100260,"startTime":"0","endTime":"0","summary":"Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSUHAMPTON, N.J., Sept.  17, 2025  (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced todaynew data demonstrating rapid","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/17/3151433/24180/en/Celldex-Presents-Data-Demonstrating-Barzolvolimab-Improves-Chronic-Spontaneous-Urticaria-Independent-of-Baseline-Immunoglobulin-E-levels-in-Phase-2-Study-at-EADV-Congress-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","BK4096","PN","AD","BK4213","CLDX","BK4139","SD"],"gpt_icon":0},{"id":"2566911092","title":"FiscalNote Holdings Issues Convertible Debentures to YA II PN","url":"https://stock-news.laohu8.com/highlight/detail?id=2566911092","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566911092?lang=en_us&edition=fundamental","pubTime":"2025-09-12 04:59","pubTimestamp":1757624380,"startTime":"0","endTime":"0","summary":"FiscalNote Holdings ( ($NOTE) ) has shared an update. On September 11, 2025, FiscalNote Holdings, Inc. issued a second tranche of convertible deben...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fiscalnote-holdings-issues-convertible-debentures-to-ya-ii-pn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fiscalnote-holdings-issues-convertible-debentures-to-ya-ii-pn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4096","BK4123","PN","NOTE"],"gpt_icon":0},{"id":"2566981120","title":"FDA Expands Approval For AstraZeneca's Drug For Pediatric Patients With Rare Type Of Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2566981120","media":"Benzinga_recent_news","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566981120?lang=en_us&edition=fundamental","pubTime":"2025-09-11 03:05","pubTimestamp":1757531100,"startTime":"0","endTime":"0","summary":"The FDA approved AstraZeneca's Koselugo for children 1+ with NF1 and inoperable nerve tumors, expanding treatment options with an established safe dose.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/09/10/Astrazeneca-U-s--Headquarters-In-Wilming.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/09/10/Astrazeneca-U-s--Headquarters-In-Wilming.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/25/09/47606676/fda-expands-approval-for-astrazenecas-drug-for-pediatric-patients-with-rare-type-of-cancer","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/25/09/47606676/fda-expands-approval-for-astrazenecas-drug-for-pediatric-patients-with-rare-type-of-cancer","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["ORR","PN","BA","LU1429558221.USD","BK4516","LU2326559502.SGD","BK4564","BK4187","BK4585","BK4551","BK4588","BK4096","LU1435385759.SGD","IE000M9KFDE8.USD"],"gpt_icon":0},{"id":"2566632938","title":"Skycorp Solar Group 1H Revenues $24,176,271, Up 7.53% YoY; Net Income $391,967, Down 39.09% YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2566632938","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566632938?lang=en_us&edition=fundamental","pubTime":"2025-09-09 04:31","pubTimestamp":1757363514,"startTime":"0","endTime":"0","summary":"Skycorp Solar Group 1H Revenues $24,176,271, Up 7.53% YoY; Net Income $391,967, Down 39.09% YoY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/09/47558605/skycorp-solar-group-1h-revenues-24-176-271-up-7-53-yoy-net-income-391-967-down-39-09-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PN","GPI"],"gpt_icon":0},{"id":"2566326376","title":"Press Release: Skycorp Solar Group Limited Reports First Half 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2566326376","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566326376?lang=en_us&edition=fundamental","pubTime":"2025-09-09 04:30","pubTimestamp":1757363400,"startTime":"0","endTime":"0","summary":"NINGBO, China, Sept. 08, 2025  -- Skycorp Solar Group Limited  , a solar PV product provider engaged in the manufacture and sale of solar cables and solar connectors, announced its financial results for the six months ended March 31, 2025.-- Revenues were $24,176,271 for the six months ended March 31, 2025. compared with $22,483,601 for the six months ended March 31, 2024,representing an increase of 7.53%, primarily driven by solar PV product. -- Gross profit was $3,703,925 for the six months ended March 31, 2025. compared with $3,395,547 for the six months ended March 31, 2024,31, 2024, as a result of our continues effort in expanding our business.representing a decrease of 39.09% from $643,498 for the six months ended. \"Our bottom-line results were shaped by accelerated investments in strategic initiatives. We significantly increased sales and marketing spend to expand into new markets, with a focus on enhancing overseas logistics and delivery. Additionally, we scaled our operational","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4096","CN","PN"],"gpt_icon":0},{"id":"2565550976","title":"Skycorp Solar Group Reports 7.53% Revenue Increase, 39.09% Net Income Decrease for First Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2565550976","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565550976?lang=en_us&edition=fundamental","pubTime":"2025-09-05 20:01","pubTimestamp":1757073715,"startTime":"0","endTime":"0","summary":"Skycorp Solar Group Ltd. has announced its financial results for the first half of 2025, revealing a notable increase in revenue driven by solar PV product sales. For the six months ending March 31, 2025, the company reported revenues of $24.18 million, up 7.53% from $22.48 million in the same period of 2024. This growth was primarily attributed to a 13.62% rise in solar PV product sales, which offset a 45.53% decline in high-performance computing product sales due to a global economic slowdown. Despite the revenue growth, Skycorp's net income decreased by 39.09%, totaling $391,967 compared to $643,498 in the prior year. The gross profit also saw an increase, reaching $3.70 million and representing 15.32% of revenues, up from 15.10% in the previous year. The company attributes this improvement to the surge in solar PV product sales. The increase in selling and marketing expenses by 23.15% to $973,207 reflects Skycorp's ongoing efforts to expand its business. There is currently no outlo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDLcctsLB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PN"],"gpt_icon":0},{"id":"2560611288","title":"Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2560611288","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560611288?lang=en_us&edition=fundamental","pubTime":"2025-08-20 04:01","pubTimestamp":1755633660,"startTime":"0","endTime":"0","summary":"Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal tractProfound mast cell depletion did not result in improved clinical outcomes p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/19/3135998/24180/en/Celldex-Reports-Results-from-Phase-2-Study-of-Barzolvolimab-in-Eosinophilic-Esophagitis-EoE.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","PN","AD","SD","BK4213","BK4096","CLDX","BK4139"],"gpt_icon":0},{"id":"2560197477","title":"Press Release: InnoCare Releases 2025 Interim Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2560197477","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560197477?lang=en_us&edition=fundamental","pubTime":"2025-08-19 22:15","pubTimestamp":1755612900,"startTime":"0","endTime":"0","summary":"InnoCare Pharma , a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2025 interim results as of 30 June 2025.Total Revenue of InnoCare increased by 74.3% year-on-year  to RMB731.4 million for the six months ended 30 June 2025, primarily attributable to the robust sales growth of orelabrutinib and license-out revenue from Prolium. Drug sales increased by 53.5% YoY to RMB641.2 million in the first half of 2025, driven by coverage expansion, an increase in the number of patients treated by orelabrutinib, especially in marginal zone lymphoma, as well as strong commercial execution. Loss for the period decreased by 86.7% to RMB35.6 million for the six months ended 30 June 2025, attributed to revenue growth and improved cost efficiency.Research and development expenses increased by 6.9% YoY to RMB449.7 million for the six months ended 30 June 2025 primarily due to increased investment in advanced technology platforms and a greater number of Ph","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","BK4199","PN","BK4022","TLS","ADC","BK4232","ITP","BK4097","OS","R","BK4096","BK4231","BK4080"],"gpt_icon":0},{"id":"2559507604","title":"Skycorp Solar Group Secures 8,705KW Solar Asset in $4.25 Million Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2559507604","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559507604?lang=en_us&edition=fundamental","pubTime":"2025-08-13 20:03","pubTimestamp":1755086598,"startTime":"0","endTime":"0","summary":"Skycorp Solar Group Ltd. has announced a definitive agreement to acquire 8,705KW of solar power stations for approximately RMB30.5 million , with the transaction expected to be completed by the end of November 2025. This acquisition will enhance the company's renewable energy operations, aligning with its long-term growth framework, the \"Pegasus Strategy,\" which focuses on building a green energy ecosystem.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skycorp Solar Group Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 13, 2025, and is solely responsible for the information c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDL90ZPsM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4096","PN"],"gpt_icon":0},{"id":"2558165403","title":"Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2558165403","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558165403?lang=en_us&edition=fundamental","pubTime":"2025-08-11 19:00","pubTimestamp":1754910000,"startTime":"0","endTime":"0","summary":"Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in mod","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/11/3130761/0/en/Kymera-Therapeutics-Announces-Second-Quarter-2025-Financial-Results-and-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACR","KYMR","IBD","EASI","LENZ","ATS","RA","BK4096","BK4007","BK4139","BK4161","BK4110","PN","BK4539"],"gpt_icon":0},{"id":"2553325578","title":"Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd","url":"https://stock-news.laohu8.com/highlight/detail?id=2553325578","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553325578?lang=en_us&edition=fundamental","pubTime":"2025-07-22 20:36","pubTimestamp":1753187760,"startTime":"0","endTime":"0","summary":"WEXFORD, Pa., July  22, 2025  (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, is pleased to an","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/22/3119443/0/en/Coeptis-COEP-Extinguishes-Convertible-Note-with-YA-II-PN-Ltd.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COEP","BK4096","PN","BK4139"],"gpt_icon":0},{"id":"2553425553","title":"Skycorp Solar Group Ltd. Embraces Cryptocurrency Payments to Enhance Global Client Experience","url":"https://stock-news.laohu8.com/highlight/detail?id=2553425553","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553425553?lang=en_us&edition=fundamental","pubTime":"2025-07-22 20:00","pubTimestamp":1753185600,"startTime":"0","endTime":"0","summary":"Ningbo, China, July  22, 2025  (GLOBE NEWSWIRE) -- Skycorp Solar Group Limited (the “Company”) (NASDAQ: PN), a solar PV product provider engaged in the manufacture and sale of solar cables and solar c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/22/3119343/0/en/Skycorp-Solar-Group-Ltd-Embraces-Cryptocurrency-Payments-to-Enhance-Global-Client-Experience.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1165135440.EUR","LU1620156130.USD","SG9999001440.SGD","LU0170899867.USD","PN","LU1543694498.USD","BK4601","LU1721427968.SGD","LU1620156213.USD","BK4585","LU1596574779.USD","BTC","LU2413666004.HKD","BK4096","BK4086","CN","ETH","BK4588","LU2413665964.HKD","MAS"],"gpt_icon":0},{"id":"2552995694","title":"European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN","url":"https://stock-news.laohu8.com/highlight/detail?id=2552995694","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552995694?lang=en_us&edition=fundamental","pubTime":"2025-07-18 23:30","pubTimestamp":1752852600,"startTime":"0","endTime":"0","summary":"– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –STAMFORD, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/18/3118039/0/en/European-Commission-Grants-Conditional-Approval-of-EZMEKLY-mirdametinib-for-the-Treatment-of-Adult-and-Pediatric-Patients-with-NF1-PN.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4156","BK4201","EC","BK4096","PN","ORR"],"gpt_icon":0},{"id":"2552431392","title":"Skycorp Solar Group Ltd. Announces Resignation of COO Gaokui Zhang Due to Health Reasons","url":"https://stock-news.laohu8.com/highlight/detail?id=2552431392","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552431392?lang=en_us&edition=fundamental","pubTime":"2025-07-18 04:00","pubTimestamp":1752782456,"startTime":"0","endTime":"0","summary":"Skycorp Solar Group Ltd. has announced the resignation of its Chief Operating Officer, Gaokui Zhang, due to health reasons. His resignation will be effective on July 17, 2025. The company clarified that his departure is not related to any disagreements or issues concerning business operations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skycorp Solar Group Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 17, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250717:nNDL4RFqLK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PN","BK4096"],"gpt_icon":0},{"id":"2548942801","title":"BRIEF-Skycorp Solar Group Announces Board Authorization For Solar Photovoltaic Power Plant Acquisitions And Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2548942801","media":"Reuters","labels":["executive","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548942801?lang=en_us&edition=fundamental","pubTime":"2025-07-03 20:00","pubTimestamp":1751544051,"startTime":"0","endTime":"0","summary":"BRIEF-Skycorp Solar Group Announces Board Authorization For Solar Photovoltaic Power Plant Acquisitions And DevelopmentJuly 3 (Reuters) - Skycorp Solar Group Ltd PN.O:SKYCORP SOLAR GROUP ANNOUNCES BOA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nTUA4ZYZTP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PN","BK4096"],"gpt_icon":0},{"id":"2539250287","title":"Intellia Says Enrollment in Late-Stage Study of NTLA-2002 on Track, of Nex-Z for ATTRv-PN Progressing Well","url":"https://stock-news.laohu8.com/highlight/detail?id=2539250287","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539250287?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:26","pubTimestamp":1748521617,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics  said late Wednesday that enrollment in its late-stage study for NTLA-2002 in hereditary angioedema remains on track, with completion expected in Q3 and a Biologics License Application filing planned for H2 next year.The company also said enrollment in the late-stage trial of nex-z for ATTRv-PN is also progressing well and that it expects to complete the study to support a potential BLA by 2028 and commercial launch by 2029.Additionally, Intellia said enrollment in its late-stage study of nex-z for ATTR-CM is progressing well as expected.Shares of the company were down by more than 20% in recent Thursday premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","SSI","NTLA","LU1861559042.SGD","BK4096","BK4556","BK4139","LU1861558580.USD","PN","BK4535"],"gpt_icon":0},{"id":"2526698416","title":"Skycorp Solar Group Limited Appoints Feng Shibo To Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2526698416","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526698416?lang=en_us&edition=fundamental","pubTime":"2025-04-11 21:01","pubTimestamp":1744376519,"startTime":"0","endTime":"0","summary":"April 11 (Reuters) - Skycorp Solar Group Ltd ::*SKYCORP SOLAR GROUP LIMITED APPOINTS FENG SHIBO TO BOARD OF DIRECTORS  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 11-APR-202512:00:00.26 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nRSD9NwqVR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PN","BK4096"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}]}}